Lead Scientist Behind Moderna COVID-19 Vaccine & Viral Immunology Pioneer
Born January 26, 1986
🇺🇸 United States Medicine & HealthcareOn January 11, 2020, Chinese scientists published the genetic sequence of a novel coronavirus that was causing a mysterious pneumonia outbreak in Wuhan. Within days, a young African American scientist at the National Institutes of Health named Dr. Kizzmekia "Kizzy" Corbett and her team had designed the key component of what would become the Moderna COVID-19 vaccine. Just 66 days after that genome sequence was published, clinical trials began. Less than a year later, the vaccine was authorized for emergency use, beginning the end of a pandemic that would kill millions worldwide.
This scientific achievement—developing a safe and effective vaccine in record time—seemed miraculous to many. But it wasn't magic or luck. It was the result of years of meticulous preparation, brilliant scientific insight, and the dedication of researchers like Dr. Corbett who had spent their careers preparing for exactly this kind of threat. When COVID-19 emerged, they were ready.
Kizzmekia Shanta Corbett was born on January 26, 1986, in Hurdle Mills, North Carolina, a small rural community. She was raised by her mother and stepfather in Hillsborough, where her fascination with science began early. Unlike many children who drift away from science as they grow older, Corbett's passion only intensified. She saw science as a way to solve real problems and help people—a perspective that would define her entire career.
Corbett attended the University of Maryland, Baltimore County (UMBC), one of the nation's leading institutions for producing Black STEM graduates. At UMBC, she majored in biological sciences and sociology, a combination that reflected her understanding that science doesn't exist in isolation from social context. She became involved in undergraduate research, working in labs and gaining hands-on experience that many undergraduates never receive.
Crucially, Corbett participated in the NIH's Meyerhoff Scholars Program and the PROPEL program, which provide research training and mentorship to students from underrepresented groups in STEM fields. These programs didn't just teach scientific techniques; they helped students see themselves as future scientists and provided the networks and support systems necessary for success in research careers. For Corbett, these experiences were transformative, setting her on the path to becoming a research scientist.
After graduating from UMBC in 2008, Corbett continued her education at the University of North Carolina at Chapel Hill, earning her PhD in microbiology and immunology in 2014. Her doctoral research focused on viral infections and immune responses—work that would prove directly relevant to her future coronavirus vaccine research. She studied how the immune system recognizes and responds to viral threats, knowledge that would be essential for designing vaccines that could trigger protective immunity.
During her graduate studies, Corbett demonstrated not just technical competence but scientific creativity—the ability to ask important questions and design elegant experiments to answer them. Her mentors recognized her exceptional potential, and she began to build a reputation as a rising star in viral immunology.
In 2014, after completing her PhD, Dr. Corbett joined the Vaccine Research Center (VRC) at the National Institute of Allergy and Infectious Diseases (NIAID), part of NIH, as a postdoctoral fellow. She worked under Dr. Barney Graham, one of the world's leading coronavirus researchers, who had been studying these viruses for years and working on vaccines for MERS (Middle East Respiratory Syndrome) and the original SARS (Severe Acute Respiratory Syndrome).
This timing was crucial. Many people assume that COVID-19 vaccine development started in January 2020, but the real work began years earlier. When MERS emerged in 2012 and killed about a third of the people it infected, researchers like Graham and Corbett began intensively studying coronavirus biology, trying to understand how these viruses infect cells and how vaccines might prevent infection.
Corbett's research focused on a specific part of the coronavirus: the spike protein that protrudes from the virus's surface like a crown (hence "corona" virus). This spike protein is critical—it's what the virus uses to attach to and enter human cells. If you can block the spike protein, you can prevent infection. But there was a problem: the spike protein is shapeshifting. It exists in different configurations, and only one of those configurations—the "prefusion" state, before it changes shape to fuse with cells—is the right target for vaccines.
Dr. Graham's lab had made a crucial discovery: they could stabilize the spike protein in its prefusion form using specific genetic modifications, creating what they called the "2P" mutation (two proline substitutions). This stabilized spike protein could be used in vaccines to trigger immune responses against the virus's most vulnerable target. Corbett became one of the leading experts in this technology, conducting experiments, analyzing data, and pushing the science forward.
By the time COVID-19 emerged, Corbett had published multiple scientific papers on coronavirus vaccines and had become the scientific lead for the VRC's Coronavirus Vaccines & Immunopathogenesis Team. She wasn't just prepared for a coronavirus pandemic—she had been specifically training for it for years.
When the SARS-CoV-2 genome sequence was published on January 11, 2020, Dr. Corbett and her NIH team immediately began applying everything they had learned from years of coronavirus research. They designed a version of the spike protein using the 2P stabilization technique they had perfected, creating the genetic sequence that would become the basis for Moderna's mRNA vaccine.
The speed was unprecedented, but it wasn't reckless. It was possible because of years of preparation. The team didn't have to figure out which viral protein to target—they knew it was the spike protein. They didn't have to figure out how to stabilize it—they had already developed that technology. They didn't have to test multiple different vaccine platforms—they knew mRNA technology worked for coronavirus vaccines because they had already tested it with MERS.
Within days, the vaccine design was complete. Within weeks, they had manufactured the first doses. On March 16, 2020—just 66 days after the genome sequence was published—the first participant in the Phase 1 clinical trial received the experimental vaccine. This was record-breaking speed, but every safety protocol was followed. No steps were skipped; they were done in parallel rather than sequentially, and years of preparatory research meant they didn't have to start from scratch.
As scientific lead, Dr. Corbett oversaw the preclinical studies that tested the vaccine in animal models before human trials began. These studies showed that the vaccine triggered strong immune responses and protected animals from infection—critical evidence that the vaccine was worth testing in humans. Her team analyzed immune responses, studied antibody levels, examined how the vaccine worked at the cellular level, and provided the scientific foundation for moving forward with human trials.
As the vaccine moved through clinical trials at warp speed, Dr. Corbett became one of the public faces of the scientific effort. This was unusual for someone at her career stage—typically, senior scientists and administrators handle public communication. But Corbett's combination of scientific expertise, communication skills, and credibility, particularly in Black and Brown communities that had historical reasons to distrust medical research, made her invaluable.
She gave countless interviews, appeared on news programs, spoke at community forums, and used social media to explain the science behind mRNA vaccines. She addressed concerns about vaccine safety, explained how the vaccines were developed so quickly without cutting corners, and emphasized that Black and Brown communities had been disproportionately affected by COVID-19 and would benefit enormously from vaccination.
This communication work wasn't separate from her science—it was essential to it. The best vaccine in the world is useless if people don't take it. Combating misinformation, addressing legitimate concerns, and building trust were as important as the laboratory research. Corbett understood that her visible presence as a young Black woman scientist could inspire trust and demonstrate that the scientific community included people from all backgrounds working to protect public health.
In December 2020, after clinical trials involving tens of thousands of participants showed that the Moderna vaccine was approximately 94% effective at preventing COVID-19 and had an acceptable safety profile, the FDA granted Emergency Use Authorization. The vaccine that Dr. Corbett and her team had designed less than a year earlier began being administered to healthcare workers, elderly Americans, and other vulnerable populations.
The impact of the COVID-19 vaccines, including the Moderna vaccine that Dr. Corbett helped develop, is difficult to overstate. Studies estimate that COVID-19 vaccines prevented more than 14 million deaths worldwide in the first year of their deployment. They allowed societies to reopen, economies to recover, and people to reunite with loved ones. They turned COVID-19 from an automatic death sentence for vulnerable populations into a manageable disease for most vaccinated people.
The mRNA vaccine technology that Moderna and Pfizer/BioNTech used—and that Dr. Corbett's team helped pioneer for coronavirus vaccines—has revolutionized vaccine development. The same platform can be quickly adapted to new viral threats, potentially allowing vaccine development for future pandemics in mere weeks rather than years. This technology is now being explored for cancer vaccines, HIV vaccines, and treatments for other diseases.
For Dr. Corbett personally, the success brought recognition and acclaim. In 2020, she was named one of TIME magazine's Heroes of the Year. She appeared on the cover of magazines, was honored with awards, and received speaking invitations from around the world. But throughout, she maintained focus on the science and on ensuring that vaccines reached the communities that needed them most.
In 2021, Dr. Corbett left NIH to join the faculty at Harvard T.H. Chan School of Public Health as an Associate Professor of Immunology and Infectious Diseases. This move allowed her to lead her own laboratory, train the next generation of scientists, and continue her coronavirus vaccine research in a new institutional setting.
At Harvard, Corbett's lab focuses on understanding how coronavirus vaccines work at the molecular level, developing improved vaccines that could provide broader protection against multiple coronavirus variants, and addressing disparities in vaccine access and uptake. She continues to study viral immunology, working to prepare for future pandemic threats while improving tools to fight current diseases.
She remains committed to diversifying STEM fields and serving as a mentor and role model for young scientists from underrepresented backgrounds. Corbett frequently speaks at universities, participates in programs supporting minority STEM students, and advocates for policies that increase diversity in scientific research. She knows from personal experience how important mentorship and support systems are for success in science, and she works to provide those opportunities for others.
Dr. Corbett's work on the Moderna COVID-19 vaccine helped save millions of lives worldwide and pioneered mRNA vaccine technology that will protect future generations from pandemic threats.
Dr. Kizzmekia Corbett's legacy is still being written, but her impact is already profound and lasting. She represents a new generation of scientists who see research not as an abstract intellectual pursuit but as a direct service to humanity, particularly to communities that have historically been underserved by medicine and science.
The COVID-19 vaccine she helped develop has been administered to hundreds of millions of people worldwide, preventing severe disease, hospitalization, and death on a massive scale. The technology underlying that vaccine—mRNA platform that can be rapidly adapted to new threats—represents a revolution in vaccine development that will benefit global health for generations. Future pandemics may be met with vaccine responses measured in weeks rather than years, thanks to the foundation Corbett and her colleagues laid.
As a young Black woman scientist leading one of the most important medical developments in modern history, Corbett has become a powerful symbol of excellence and possibility. She demonstrates that scientific genius exists in every community and that diversity in science isn't just a matter of fairness—it's essential for solving humanity's greatest challenges. Her visible leadership during the pandemic has inspired countless young people, especially young women of color, to pursue careers in STEM fields.
Corbett's commitment to science communication and health equity has helped address vaccine hesitancy and misinformation, particularly in communities that have historical reasons to distrust medical research. By being a credible, relatable spokesperson who understands both the science and the social context, she has built bridges between scientific institutions and communities that have often been excluded or exploited by those institutions.
At Harvard, Corbett continues to push the boundaries of viral immunology while training the next generation of scientists. Her laboratory works on improving coronavirus vaccines, understanding immune responses, and preparing for future viral threats. She remains committed to ensuring that scientific advances benefit all communities, not just the privileged few, and to creating pathways for diverse students to succeed in science.
Perhaps most importantly, Dr. Corbett has shown that preparation matters. The "miracle" of rapid COVID vaccine development wasn't miraculous—it was the result of years of unglamorous, painstaking research on diseases that weren't making headlines. When the crisis came, scientists like Corbett were ready because they had been preparing. Her career demonstrates the value of investing in basic research, supporting young scientists, and maintaining robust public health infrastructure even when there's no immediate crisis. These investments save lives when pandemics strike.
Discover the fascinating journey of this groundbreaking invention - from initial ideation and brainstorming, through prototyping and manufacturing challenges, to its distribution and early days in the market. Learn about the world-changing impact it has had on society.
Our comprehensive invention page covers: